Product
RLY-1971
1 clinical trial
3 indications
Indication
Solid TumorIndication
UnspecifiedIndication
AdultClinical trial
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-11-22